GlassScriptPhysician profile
Faina Akselrod
NPI 1528035862
$2,894.66
in general payments reported to CMS, 2019-2025
26 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $320 · 2021: $431 · 2022: $545 · 2023: $461 · 2024: $544 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.50 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $363.66 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $339.06 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $272.70 | 2019-2024 | |
| Coopersurgical, INC. | $223.56 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $134.65 | 2019-2025 | Slynd |
| Urovant Sciences INC | $124.35 | 2022 | |
| Evofem Biosciences, INC. | $110.23 | 2021-2024 | Phexxi |
| Therapeuticsmd, INC. | $109.23 | 2019-2022 | |
| Novo Nordisk INC | $98.88 | 2020-2024 | Ozempic |
| Myovant Sciences INC. | $84.91 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $80.02 | 2023-2025 | |
| Hologic Sales and Service, LLC | $73.56 | 2021-2025 | Aptima |
| Avion Pharmaceuticals | $71.25 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $61.87 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $40.93 | 2022-2024 | |
| Lupin INC. | $32.42 | 2020-2021 | |
| Myriad Women'S Health, INC. | $27.46 | 2023 | Myrisk |
| Scynexis, INC. | $25.00 | 2022 | |
| Mylan Pharmaceuticals INC. | $24.92 | 2020 | |
| Biogen, INC. | $22.73 | 2025 | Zurzuvae |
| Duchesnay USA Incorporated | $22.08 | 2019 | |
| Amag Pharmaceuticals, INC. | $22.00 | 2019 | |
| Shield Therapeutics INC | $20.79 | 2023 | Accrufer |
| Agile Therapeutics, INC. | $15.35 | 2021 | |
| Millicent US INC | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faina Akselrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.